SIWA THERAPEUTICS

siwa-therapeutics-logo

They founded SIWA in 2006 to develop biological therapies, including their proprietary humanized monoclonal antibody, SIWA 318H, for slowing or reversing the aging process through the removal of SCs. SCs are causally implicated in age-related dysfunction and in degenerative disease. These cells act primarily by secreting substances which interfere with normal functions of other cells; thus, removing them has been shown to improve healthspan and lifespan.

#People #Website #More

SIWA THERAPEUTICS

Social Links:

Industry:
Biotechnology Therapeutics

Founded:
2006-01-01

Address:
Chicago, Illinois, United States

Country:
United States

Website Url:
http://www.siwatherapeutics.com

Total Employee:
1+

Status:
Active

Contact:
+1 (312) 445-8529

Email Addresses:
[email protected]

Total Funding:
1.63 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins



Current Advisors List

not_available_image

Alex Kormushoff Board Member @ SIWA Therapeutics
Board_member

Current Employees Featured

not_available_image

Misty Gruber
Misty Gruber CFO and Co-Founder @ SIWA Therapeutics
CFO and Co-Founder
2007-08-01

not_available_image

Lewis S. Gruber
Lewis S. Gruber CEO and CSO and Co-Founder @ SIWA Therapeutics
CEO and CSO and Co-Founder
2007-10-01

jim-alvarez_image

Jim Alvarez
Jim Alvarez Chief Operating Officer @ SIWA Therapeutics
Chief Operating Officer
2019-05-01

Founder


not_available_image

Lewis S. Gruber

not_available_image

Misty Gruber

Official Site Inspections

http://www.siwatherapeutics.com

  • Host name: eos.springshosting.net
  • IP address: 192.30.131.114
  • Location: Colorado Springs United States
  • Latitude: 38.9129
  • Longitude: -104.7794
  • Metro Code: 752
  • Timezone: America/Denver
  • Postal: 80918

Loading ...

More informations about "SIWA Therapeutics"

Siwa Therapeutics โ€“ A Preclinical Stage Biotechnology โ€ฆ

Siwa Therapeutics is a preclinical stage biotechnology company developing innovative therapies targeting cancer and other diseases.See details»

SIWA Therapeutics - Crunchbase Company Profile & Funding

Contact Email [email protected] Phone Number +1 (312) 445-8529 They founded SIWA in 2006 to develop biological therapies, including their proprietary humanized โ€ฆSee details»

Leadership - Siwa Therapeutics

Leadership. Lewis S. Gruber is CEO, Chief Scientific Officer and Co-Founder of SIWA Therapeutics.He is also the named inventor on all of SIWA Therapeuticsโ€™ portfolio of more โ€ฆSee details»

SIWA Therapeutics Company Profile | Management and โ€ฆ

Www.siwatherapeutics.com . Contact Information. Headquarters. Chicago, Illinois, United States (312) 445-8529. SIWA Therapeutics Profile and History . SIWA Therapeutics, Inc. is focused โ€ฆSee details»

New antibody shows strong potential against pancreatic cancer

Oct 12, 2023 Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing โ€ฆSee details»

SIWA Therapeutics - 2025 Company Profile - Tracxn

Mar 23, 2025 SIWA Therapeutics is developing a monoclonal antibody that targets and destroys senescent cells. The company lead product SIWA 318, targets a naturally-occurring โ€ฆSee details»

SIWA Therapeutics - Craft

SIWA Therapeutics $1.6 m in total funding,. See insights on SIWA Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»

SIWA Therapeutics - Overview, News & Similar companies

Feb 23, 2022 SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study SIWA's Proprietary Humanized Monoclonal Antibody, SIWA318H, is Efficacious in an โ€ฆSee details»

SIWA Therapeutics - VentureRadar

"SIWA Therapeutics, Inc. is a pre-clinical stage company with: A first-in-class humanized monoclonal antibody (โ€œmAbโ€), SIWA 318H, that selectively targets both senescent cells โ€ฆSee details»

Siwa Corp. - Drug pipelines, Patents, Clinical trials - Synapse

Explore Siwa Corp. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Endocrinology and Metabolic Disease, Neoplasms, Technology Platform ...See details»

SIWA Therapeutics Overview | SignalHire Company Profile

SIWA Therapeutics is a private company that has been in the industry for 17 years. The company currently specializes in the Biotechnology, Biotechnology, Medical Research & Laboratories โ€ฆSee details»

SIWA Therapeutics Company Overview, Contact Details

May 22, 2017 [email protected]: 29%. See more formats. Frequently Asked Questions Where is SIWA Therapeutics 's headquarters located? SIWA Therapeutics 's main โ€ฆSee details»

SIWA Therapeutics - LinkedIn

SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells.See details»

SIWA Therapeutics - Company Profile & Staff Directory - ContactOut

SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus โ€ฆSee details»

SIWA Therapeutics - PitchBook

Information on valuation, funding, cap tables, investors, and executives for SIWA Therapeutics. Use the PitchBook Platform to explore the full profile.See details»

SIWA Therapeutics - Products, Competitors, Financials, Employees ...

Headquarters Location. 400 E. Randolph Suite 3911. Chicago, Illinois, 60601, United States. 312-543-7172See details»

Siwa Therapeutics - Company info. interviews, news

SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells.See details»

SIWA Therapeutics To Participate in September Investor Conferences

Sep 16, 2020 More information is available at www.siwatherapeutics.com. Contacts. Ellyn Caruso | [email protected] Sally Leaf | [email protected] 312-854-7079 Release Summary.See details»

SIWA Therapeutics Announces Promising Results in New โ€ฆ

Mar 14, 2022 SIWA's Proprietary Humanized Monoclonal Antibody, SIWA318H, is Efficacious in an Immune Competent Humanized Mouse Xenograft Model for Pancreatic Cancer. CHICAGO, โ€ฆSee details»

News - Siwa Therapeutics

CHICAGO, Feb. 24, 2022 /PRNewswire/ -- SIWA THERAPEUTICS, INC, which has developed SIWA318H, a proprietary monoclonal antibody that has caused complete remission of โ€ฆSee details»